Bicara Therapeutics Inc. 4

CEO Claire Mazumdar of Bicara Therapeutics Inc. exercised 10,000 options and sold 10,000 shares of common stock around $28–$30 per share under a Rule 10b5-1 plan.

On July 10, 2026, Bicara Therapeutics Inc. CEO Claire Mazumdar exercised 10,000 stock options with a strike price of $3.7898, acquiring 10,000 shares of common stock, and on the same day sold essentially all of those 10,000 shares in two transactions: 9,972 shares at a weighted average price of $28.4163 and 28 shares at $29.68, pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. The option exercise appears to be part of a scheduled vesting program, with the underlying option originally vesting in sixteen equal quarterly installments following April 5, 2023. After these transactions, she directly owned 362,152 shares of Bicara common stock, with an implied holding value of roughly $10.3 million using the sale price of about $28.4 per share.

Filing Facts

CIK

2023658

Ticker

BCAX

Form

4

Source Type

fda

Accession

0001470831-26-000714

Alert Tier

6